The company can again ship the Duchenne gene therapy for patients who can still walk, following a one-week pause triggered by ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

The deal, which will focus first on a COPD therapy GSK believes holds “best-in-class” potential, could ultimately involve a ...

By nature, GenAI generates content probabilistically, meaning responses might vary slightly each time. But for life sciences ...

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency ...

TCG Labs Soleil, which launched in 2024 in collaboration with The Column Group, is focused on building single-drug biotechs ...